New Issue: SOL-LION, Fondo de Titulizacion de Activos

  • ID: 1713660
  • June 2009
  • Standard & Poors
1 of 3

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Standard & Poor's Ratings Services has assigned credit ratings to the -4,500 million mortgage-backed floating-rate notes issued by SOL-LION, Fondo de Titulizaci-n de Activos (SOL-LION), the first securitization of prime mortgage loans originated by ING Direct N.V. in Spain. SOL-LION acquired credit rights backed by mortgage loans. To fund this purchase, it issued three classes of floating-rate notes. A reserve fund (1.50%) was funded at closing through a participative loan. The transaction aims to insulate the assets from originator or "sociedad gestora" (fund manager) insolvency. The originator of the assets is the Spanish branch of ING Direct, N.V., which was set up in 1999. Its local business is based on residential mortgages, personal loans, credit cards, and trade discounts. At...

Companies mentioned in this report are: SOL-LION, Fondo de Titulizacion de Activos
Action: New Rating

Note: Product cover images may vary from those shown
2 of 3

SOL-LION, Fondo de Titulizacion de Activos

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.